Allergan's Botox fine: Good marketing?

Allergan launched a marketing campaign to promote Botox for treating migraines, despite the fact that the FDA never gave it the green light. As punishment, the company received a bill for $600 million -- in the form of a fine and settlment -- from the Department of Justice.

Migraine diagnosed in error before death

PATIENTS WHO present at hospitals with persistent and severe headaches should receive Cat scans within a minimum timeframe, a jury at the inquest of a 21-year-old woman who died from a massive brain haemorrhage has recommended.

MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment In Open-Label Trial And Completion Of ...

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX. At this time, all patients have been ...

Cape weather: Maybe no rain headache?

The National Weather Service says today will be partly sunny with highs in the mid 70s and southwest winds 15 to 20 mph, while tonight will be partly cloudy with lows in the 60s.

Nautilus Neurosciences And APR Applied Pharma Research s.a. Announce Extension Of Patent Protection For CAMBIA™ ...

Nautilus Neurosciences, Inc. ("Nautilus"), a neurology-focused specialty pharmaceutical company headquartered in New Jersey, and APR Applied Pharma Research s.a. ("APR"), a leading drug developer and delivery technology provider based in Switzerland, announced today that CAMBIA™ (diclofenac potassium for oral solution) is now protected by an additional Orange Book listed patent through June 16 ...

Treat pain as a 'disease', expert says

About 80 per cent of people with chronic pain do not get adequate relief and are suffering needlessly throughout the world, a leading pain authority said Friday.